Highly functionalized 2-oxopiperazine-based peptidomimetics: An approach to PAR1 antagonists

Structure-based QSAR, molecule design and bioassays of protease-activated receptor 1 inhibitors

Quantitative structure-activity relationship (QSAR) studies were performed on a series of protease-activated receptor 1 (PAR1) inhibitors to identify the key structural features responsible for their biological activity. Induced-fit docking (IFD) was used to explore the active mechanisms of all PAR1 inhibitors at the active pocket of PAR1, and the best plausible conformation was determined by IFD for further QSAR studies. Based on the best plausible conformation, structure-based descriptors and ligand descriptors incorporating the ligand-receptor interaction were calculated. The random forest method was used to select important descriptors and build the 2D-QSAR model. The results of the 2D-QSAR model gave a squared correlation coefficient (R²) of 0.937, a prediction squared correlation coefficient (R²_pred) of 0.845 and a mean square error (MSE) of 0.056. Furthermore, a 3D-QSAR model was developed via topomer comparative molecular field analysis (Topomer CoMFA), resulting in an R² of 0.938, a cross-validated Q² of 0.503 and a R²_pred of 0.758. Based on the developed QSAR model, Topomer search was used for virtual screening of the R2 fragment in lead-like inhibitors from the National Cancer Institute (NCI) database, which contains 260,000 molecules. Eighty-two compounds were designed with different R2 fragments, and four of these compounds were selected for further biological testing. All four compounds showed inhibitory potency against PAR1.

Two-step one-pot synthesis of dihydropyrazinones as Xaa-Ser dipeptide isosteres through morpholine acetal rearrangement

The synthesis of the uncommon dihydropyrazinone ring was accomplished by taking advantage of the ring rearrangement ofN-acylated morpholine acetal derived from serine under acidic treatment and in the presence of 2,6-lutidine, resulting in a constrained Xaa-Ser dipeptide isostere.

Exploring the Phe-Gly dipeptide-derived piperazinone scaffold in the search for antagonists of the thrombin receptor PAR1

A series of Phe-Gly dipeptide-derived piperazinones containing an aromatic urea moiety and a basic amino acid has been synthesized and evaluated as inhibitors of human platelet aggregation induced by the PAR1 agonist SFLLRN and as cytotoxic agents in human cancer cells. The synthetic strategy involves coupling of a protected basic amino acid benzyl amide to 1,2- and 1,2,4-substituted-piperazinone derivatives, through a carbonylmethyl group at the N_1-position, followed by formation of an aromatic urea at the exocyclic moiety linked at the C₂ position of the piperazine ring and removal of protecting groups. None of the compounds showed activity in the biological evaluation.